Grünenthal USA Inc.
Partner in Pain Management
Grünenthal USA is a subsidiary of Grünenthal GmbH, an independent, family-owned pharmaceutical company specializing in pain management.
Grünenthal USA partners with other leading pharmaceutical companies to deliver innovative products to patients living with pain.
Address:
Grünenthal USA, Inc.
360 Mount Kemble Avenue
Morristown, NJ 07960
908-306-0024 (phone)
908-306-1631 (fax)
New Chief Commercial Officer Grünenthal Group
Mark Fladrich takes office as the new CCO as of
The Grünenthal Group announces that Mark Fladrich has taken office as new Chief Commercial Officer (CCO).
In his last appointment Mark Fladrich served as Area Vice President, Southern and Western Europe for AstraZeneca.
His aspiration is to bring the Global Commercial functions closer to the markets and to foster the interface between Commercial and R&D.
Grünenthal focusses on developing new therapies/medicines for patients. In order to make these therapies/medicines available to patients, Grünenthal is conducting rigorous clinical trials to assess the safety and efficacy of the investigational therapies/medicines, which if proven, will enable the necessary approvals from regulatory authorities. This process will allow patients to have broad access to these medicines. We encourage patients who want access to our investigational therapies/medicines to participate in our clinical trial programs. Given the investigational status of our compounds in clinical development, we currently do not grant expanded access.